Fran Schulz Purchases 10,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) Director Fran Schulz purchased 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, with a total value of $47,500.00. Following the transaction, the director directly owned 15,100 shares of the company’s stock, valued at approximately $71,725. The trade was a 196.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

FocalTherics Stock Down 2.3%

Shares of FOCL stock opened at $4.26 on Wednesday. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The firm has a market capitalization of $159.66 million, a P/E ratio of -4.14 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The company’s 50 day moving average is $5.38.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million during the quarter. As a group, equities analysts expect that FocalTherics will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on FOCL. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler reiterated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday. Finally, Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.75.

Hedge Funds Weigh In On FocalTherics

Several large investors have recently added to or reduced their stakes in the company. Flax Pond Capital LLC bought a new stake in shares of FocalTherics in the 4th quarter worth approximately $2,623,000. Rock Springs Capital Management LP increased its position in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares during the period. Kovack Advisors Inc. acquired a new position in shares of FocalTherics in the fourth quarter valued at $53,000. Leonteq Securities AG acquired a new position in shares of FocalTherics in the fourth quarter valued at $313,000. Finally, Lido Advisors LLC bought a new position in FocalTherics in the first quarter worth $40,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Key FocalTherics News

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.